DUBLIN, May 13, 2024 (Globe Newswire) — The “Lifestyle Drugs – Global Strategic Business Report'' report has been added. ResearchAndMarkets.com Recruitment.
Global lifestyle drug market expected to reach $46 billion by 2030
The global market for lifestyle drugs, estimated at USD 37.3 billion in 2023, is projected to reach an adjusted size of USD 46 billion by 2030, increasing by 3.1% over the analysis period 2023-2030. It is predicted to grow at a CAGR.
Lifestyle medicines for obesity, one of the segments analyzed in the report, is expected to register a CAGR of 3.6% and reach USD 19.5 billion by the end of the analysis period. The growth of the dermatology lifestyle pharmaceuticals sector is estimated at 2.7% CAGR over the next seven years.
The US market is estimated at $11.2 billion, while China is projected to grow at a CAGR of 2.9%
The U.S. lifestyle drug market is estimated at USD 11.2 billion in 2023. China, the world's second largest economy, is expected to reach a projected market size of USD 8.2 billion by 2030, trending at a CAGR of 2.9% over 2030. . The analysis period is from 2023 to 2030. Other notable geographic markets include Japan and Canada, which are expected to grow by 2.9% and 2.5%, respectively, over the 2023-2030 period. Among Europe, Germany is projected to grow at a CAGR of approximately 3.2%.
Key attributes:
report attributes | detail |
number of pages | 184 |
Forecast period | 2023-2030 |
Estimated market value in 2023 (USD) | $37.3 billion |
Projected market value to 2030 (USD) | $46 billion |
compound annual growth rate | 3.1% |
Target area | global |
Main topics covered:
I. Methodology
II. Executive Summary
1. Market overview
- Insights into the influencer market
- Global market trajectory
- Lifestyle Drugs – Market Share Percentage of Global Major Competitors in 2024 (E)
- Latest information on the world economy
- Competitive Market Presence – Strong/Active/Niche/Mediocre (E) for Players Worldwide in 2024
Focus on carefully selected players(22 total)
- Alembic Pharmaceuticals Limited
- amgen company
- AstraZeneca PLC
- Biocon Co., Ltd.
- Cipla Co., Ltd.
- Dr. Reddy's Laboratories Co., Ltd.
- Eli Lilly and Company
- GlaxoSmithKline PLC
- johnson & johnson
- Lupine Co., Ltd.
- Merck & Co.
- Mylan Pharmaceuticals Co., Ltd.
- Novo Nordisk A/S
- Pfizer Japan Inc
- Piramal Enterprises Limited
- Procter & Gamble Company,
- Sun Pharmaceutical Industry Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Zydus Cadira
For more information on this report, please visit https://www.researchandmarkets.com/r/ubff2y.
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.